pioglitazone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peroxisome proliferator activating receptor-gamma (PPAR-gamma) agonists, thiazolidinedione derivatives 2179 111025-46-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pioglitazone
  • glustin
  • sepioglin
  • pioglitazone hydrochloride
  • pioglitazone HCl
Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.
  • Molecular weight: 356.44
  • Formula: C19H20N2O3S
  • CLOGP: 3.53
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 68.29
  • ALOGS: -4.91
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.80 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.01 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
July 15, 1999 FDA TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bladder cancer 538.02 11.95 159 22839 5407 63460617
Hypoglycaemia 448.33 11.95 276 22722 59789 63406235
Blood glucose increased 401.01 11.95 292 22706 83464 63382560
Cardiac failure congestive 187.97 11.95 198 22800 92235 63373789
Diabetes mellitus inadequate control 145.48 11.95 82 22916 15044 63450980
Glycosylated haemoglobin increased 140.76 11.95 75 22923 12323 63453701
Blood glucose decreased 128.07 11.95 85 22913 20867 63445157
Diabetic ketoacidosis 124.88 11.95 83 22915 20422 63445602
Oedema peripheral 113.68 11.95 227 22771 189284 63276740
Cardiac failure 84.96 11.95 131 22867 89011 63377013
Diabetic metabolic decompensation 79.35 11.95 28 22970 1682 63464342
Lactic acidosis 72.41 11.95 79 22919 38208 63427816
Pancreatitis 67.48 11.95 86 22912 48969 63417055
Systemic lupus erythematosus 63.11 11.95 3 22995 208915 63257109
Drug intolerance 62.98 11.95 17 22981 308644 63157380
Drug ineffective 61.87 11.95 185 22813 1044580 62421444
Myocardial infarction 61.41 11.95 121 22877 99772 63366252
Hyperglycaemia 58.53 11.95 74 22924 41793 63424231
Oedema 58.50 11.95 117 22881 97505 63368519
Bladder neoplasm 56.89 11.95 17 22981 599 63465425
Weight increased 54.14 11.95 212 22786 260580 63205444
Infusion related reaction 53.03 11.95 12 22986 245509 63220515
Glossodynia 52.66 11.95 3 22995 178873 63287151
Off label use 51.92 11.95 104 22894 674358 62791666
Bladder transitional cell carcinoma 51.34 11.95 16 22982 651 63465373
Macular oedema 51.30 11.95 26 22972 3851 63462173
Contraindicated product administered 48.30 11.95 10 22988 217638 63248386
Maternal exposure during pregnancy 47.03 11.95 11 22987 220051 63245973
Acute kidney injury 46.69 11.95 204 22794 263211 63202813
Pancreatitis acute 46.12 11.95 53 22945 27113 63438911
Coronary artery disease 43.32 11.95 56 22942 32321 63433703
Arthropathy 40.78 11.95 17 22981 234775 63231249
Diabetes mellitus 39.73 11.95 72 22926 55738 63410286
Pancreatic carcinoma 39.62 11.95 28 22970 7600 63458424
Wound 39.47 11.95 6 22992 163257 63302767
Weight decreased 39.28 11.95 201 22797 276597 63189427
Renal failure 37.02 11.95 110 22888 117542 63348482
Treatment failure 36.91 11.95 13 22985 199030 63266994
Alopecia 35.53 11.95 42 22956 337494 63128530
Diabetic retinopathy 34.92 11.95 17 22981 2310 63463714
Lower respiratory tract infection 34.04 11.95 4 22994 132303 63333721
Hypoglycaemic coma 33.29 11.95 17 22981 2558 63463466
Rheumatoid arthritis 33.20 11.95 26 22972 253793 63212231
Discomfort 32.66 11.95 10 22988 167364 63298660
Therapeutic product effect decreased 31.94 11.95 15 22983 193172 63272852
Ureteric cancer 31.71 11.95 7 22991 70 63465954
Product complaint 30.65 11.95 30 22968 12779 63453245
Joint swelling 30.17 11.95 45 22953 327621 63138403
Product use issue 29.59 11.95 22 22976 220498 63245526
Asthenia 29.24 11.95 238 22760 383366 63082658
Blood glucose fluctuation 29.01 11.95 19 22979 4557 63461467
Bladder trabeculation 27.75 11.95 6 22992 54 63465970
Bladder adenocarcinoma stage unspecified 27.45 11.95 5 22993 16 63466008
Pericarditis 27.27 11.95 7 22991 131572 63334452
Fall 26.52 11.95 237 22761 392097 63073927
Myalgia 26.31 11.95 114 22884 146415 63319609
Chest pain 25.99 11.95 150 22848 215809 63250215
Angina unstable 25.69 11.95 21 22977 7074 63458950
General physical health deterioration 24.64 11.95 22 22976 201380 63264644
Biopsy skin abnormal 24.41 11.95 6 22992 99 63465925
Abdominal discomfort 24.15 11.95 50 22948 320835 63145189
Musculoskeletal stiffness 24.02 11.95 19 22979 184599 63281425
Diabetic neuropathy 24.01 11.95 16 22982 3948 63462076
Dehydration 23.93 11.95 125 22873 173229 63292795
Therapeutic product effect incomplete 23.46 11.95 8 22990 125048 63340976
Pancreatitis chronic 22.62 11.95 13 22985 2471 63463553
Nausea 22.56 11.95 434 22564 854037 62611987
Portal fibrosis 22.43 11.95 7 22991 286 63465738
Blood triglycerides increased 22.27 11.95 25 22973 12463 63453561
Cholelithiasis 22.05 11.95 49 22949 43876 63422148
Haematuria 21.23 11.95 38 22960 29119 63436905
Vomiting 20.92 11.95 301 22697 559316 62906708
Fasting 20.71 11.95 4 22994 19 63466005
Radius fracture 20.42 11.95 14 22984 3621 63462403
Ketoacidosis 20.29 11.95 15 22983 4363 63461661
Euglycaemic diabetic ketoacidosis 20.28 11.95 14 22984 3660 63462364
Dyspnoea 20.28 11.95 344 22654 660969 62805055
Exposure during pregnancy 20.24 11.95 16 22982 155531 63310493
Fluid retention 19.90 11.95 57 22941 59629 63406395
Acute myocardial infarction 19.82 11.95 39 22959 32085 63433939
Nasopharyngitis 19.65 11.95 39 22959 254218 63211806
High density lipoprotein decreased 18.81 11.95 11 22987 2159 63463865
Pancreatic carcinoma metastatic 18.78 11.95 11 22987 2167 63463857
Tibia fracture 18.21 11.95 15 22983 5105 63460919
Blood ketone body increased 18.18 11.95 6 22992 294 63465730
Infection 17.84 11.95 35 22963 229138 63236886
Hepatic enzyme increased 17.45 11.95 29 22969 202299 63263725
Ketosis 17.38 11.95 7 22991 606 63465418
Arteriosclerosis coronary artery 17.09 11.95 18 22980 8355 63457669
Intentional product use issue 16.83 11.95 13 22985 127879 63338145
Transitional cell carcinoma 16.81 11.95 7 22991 660 63465364
IIIrd nerve paralysis 16.50 11.95 7 22991 691 63465333
Varicose vein ruptured 16.27 11.95 4 22994 66 63465958
Nicotinic acid deficiency 16.16 11.95 4 22994 68 63465956
Renal impairment 16.04 11.95 69 22929 88286 63377738
Incorrect dose administered 16.02 11.95 53 22945 59915 63406109
Retinal aneurysm 15.98 11.95 5 22993 206 63465818
Stomatitis 15.97 11.95 16 22982 138709 63327315
Rhabdomyolysis 15.66 11.95 43 22955 43908 63422116
Face oedema 15.57 11.95 27 22971 20185 63445839
Visual acuity reduced 15.32 11.95 28 22970 21798 63444226
Ankle fracture 15.28 11.95 25 22973 17830 63448194
Rash 15.24 11.95 130 22868 560741 62905283
Shock 15.10 11.95 29 22969 23434 63442590
Unresponsive to stimuli 15.07 11.95 36 22962 33780 63432244
Left ventricular dysfunction 14.89 11.95 20 22978 11968 63454056
Inflammatory bowel disease 14.89 11.95 12 22986 3961 63462063
Decreased appetite 14.60 11.95 147 22851 250905 63215119
Swelling 14.59 11.95 51 22947 275327 63190697
Hyperkalaemia 14.56 11.95 48 22950 54155 63411869
Blood glucose abnormal 14.42 11.95 16 22982 7876 63458148
Arteriosclerosis 14.39 11.95 18 22980 10048 63455976
Hypersensitivity 14.33 11.95 56 22942 292629 63173395
Acute coronary syndrome 14.31 11.95 18 22980 10108 63455916
Postmortem blood drug level increased 14.09 11.95 6 22992 598 63465426
Adult failure to thrive 13.97 11.95 4 22994 121 63465903
Fibula fracture 13.92 11.95 11 22987 3531 63462493
Cerebrovascular accident 13.61 11.95 76 22922 107948 63358076
Upper airway obstruction 13.21 11.95 6 22992 697 63465327
Cardiomegaly 12.88 11.95 23 22975 17591 63448433
Pain 12.86 11.95 190 22808 740438 62725586
Salpingo-oophorectomy bilateral 12.80 11.95 4 22994 164 63465860
Urine output decreased 12.67 11.95 18 22980 11352 63454672
Retinal haemorrhage 12.57 11.95 12 22986 4957 63461067
Contraindicated product prescribed 12.24 11.95 7 22991 1318 63464706
Gastrointestinal disorder 12.08 11.95 18 22980 131221 63334803
Pleural effusion 12.02 11.95 66 22932 93144 63372880
Generalised oedema 12.01 11.95 21 22977 15797 63450227
Cardiac failure acute 12.00 11.95 16 22982 9507 63456517
Sinusitis 11.99 11.95 42 22956 226611 63239413
Hypertriglyceridaemia 11.97 11.95 13 22985 6246 63459778

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bladder cancer 2327.20 12.22 737 24783 15541 34915870
Bladder transitional cell carcinoma 389.72 12.22 123 25397 2532 34928879
Blood glucose increased 261.23 12.22 281 25239 66437 34864974
Hypoglycaemia 251.44 12.22 251 25269 54389 34877022
Cardiac failure congestive 148.24 12.22 238 25282 83032 34848379
Diabetes mellitus inadequate control 141.97 12.22 100 25420 13364 34918047
Pancreatitis 136.79 12.22 155 25365 38736 34892675
Glycosylated haemoglobin increased 128.26 12.22 88 25432 11272 34920139
Oedema peripheral 102.66 12.22 252 25268 119560 34811851
Haematuria 100.02 12.22 151 25369 49915 34881496
Pancreatic carcinoma 88.96 12.22 64 25456 8837 34922574
Diabetic ketoacidosis 84.94 12.22 84 25436 17948 34913463
Bladder neoplasm 82.98 12.22 33 25487 1355 34930056
Off label use 69.90 12.22 125 25395 419399 34512012
Blood glucose decreased 66.72 12.22 64 25456 13173 34918238
Myocardial infarction 63.03 12.22 213 25307 120872 34810539
Transitional cell carcinoma 62.54 12.22 31 25489 2158 34929253
Macular oedema 54.20 12.22 31 25489 2883 34928528
Ureteric cancer 48.90 12.22 14 25506 203 34931208
Drug ineffective 48.10 12.22 172 25348 456579 34474832
Weight increased 46.92 12.22 162 25358 92871 34838540
Toxicity to various agents 46.11 12.22 47 25473 200315 34731096
Oedema 45.38 12.22 102 25418 45639 34885772
Malignant spinal cord compression 43.93 12.22 12 25508 145 34931266
Diabetic nephropathy 43.26 12.22 24 25496 2104 34929307
Hyperglycaemia 41.38 12.22 90 25430 39390 34892021
Pancreatitis acute 40.15 12.22 73 25447 28068 34903343
Product use in unapproved indication 39.76 12.22 18 25502 117481 34813930
Coronary artery disease 38.54 12.22 99 25421 48206 34883205
Bladder cancer recurrent 36.55 12.22 13 25507 390 34931021
Genital infection fungal 36.21 12.22 11 25509 198 34931213
Bladder cancer stage 0, with cancer in situ 35.48 12.22 8 25512 40 34931371
Diabetic metabolic decompensation 30.75 12.22 18 25502 1748 34929663
Pemphigoid 29.52 12.22 34 25486 8632 34922779
Meningitis eosinophilic 29.29 12.22 6 25514 17 34931394
Product complaint 28.77 12.22 28 25492 5862 34925549
Acute myocardial infarction 28.33 12.22 95 25425 53624 34877787
Diabetic retinopathy 27.69 12.22 17 25503 1800 34929611
Gallbladder neoplasm 26.45 12.22 6 25514 31 34931380
Death 26.10 12.22 177 25343 397872 34533539
Hypoglycaemic coma 25.48 12.22 18 25502 2413 34928998
General physical health deterioration 25.27 12.22 34 25486 128235 34803176
Euglycaemic diabetic ketoacidosis 25.17 12.22 20 25500 3202 34928209
Intentional product use issue 23.88 12.22 7 25513 59809 34871602
Treatment failure 23.82 12.22 3 25517 46694 34884717
Cerebral infarction 23.70 12.22 58 25462 27397 34904014
Bladder papilloma 21.70 12.22 5 25515 28 34931383
Cardiac failure 20.99 12.22 126 25394 91122 34840289
Infectious mononucleosis 20.87 12.22 10 25510 646 34930765
Urethral cancer 20.47 12.22 6 25514 95 34931316
Renal cyst 20.41 12.22 29 25491 9064 34922347
Pleural effusion 20.31 12.22 115 25405 81431 34849980
Anti-insulin antibody positive 20.31 12.22 7 25513 191 34931220
Overdose 20.19 12.22 22 25498 91037 34840374
Malignant neoplasm of renal pelvis 19.94 12.22 5 25515 42 34931369
Pollakiuria 19.64 12.22 44 25476 19630 34911781
Bladder transitional cell carcinoma stage III 19.44 12.22 5 25515 47 34931364
Cerebrovascular accident 18.80 12.22 116 25404 84695 34846716
Weight decreased 18.78 12.22 204 25316 176097 34755314
Diabetic neuropathy 18.74 12.22 19 25501 4178 34927233
Urine cytology abnormal 18.67 12.22 3 25517 0 34931411
Type 2 diabetes mellitus 18.47 12.22 38 25482 15994 34915417
Thrombocytopenia 18.29 12.22 56 25464 156191 34775220
Bladder transitional cell carcinoma stage II 18.26 12.22 5 25515 61 34931350
Foetal exposure during pregnancy 18.15 12.22 3 25517 38098 34893313
Product use issue 18.01 12.22 12 25508 63204 34868207
Hepatic cancer 18.00 12.22 26 25494 8249 34923162
Pulmonary oedema 17.54 12.22 75 25445 47454 34883957
Pyrexia 16.74 12.22 159 25361 332854 34598557
Blood creatine phosphokinase increased 16.72 12.22 71 25449 44786 34886625
Abnormal weight gain 16.60 12.22 10 25510 1024 34930387
Prostate cancer 16.55 12.22 65 25455 39584 34891827
Blood glucose abnormal 16.44 12.22 21 25499 5931 34925480
Drug intolerance 16.06 12.22 12 25508 59558 34871853
Metastatic carcinoma of the bladder 15.97 12.22 6 25514 211 34931200
Post-thoracotomy pain syndrome 15.71 12.22 4 25516 36 34931375
Interstitial lung disease 15.55 12.22 91 25429 65191 34866220
Bladder adenocarcinoma stage unspecified 15.38 12.22 3 25517 6 34931405
Febrile neutropenia 15.34 12.22 50 25470 136799 34794612
Angina pectoris 15.25 12.22 54 25466 31309 34900102
Isosporiasis 15.23 12.22 5 25515 117 34931294
Retinal aneurysm 14.99 12.22 5 25515 123 34931288
Insulin resistance 14.98 12.22 8 25512 650 34930761
Loss of consciousness 14.67 12.22 107 25413 82560 34848851
Angina unstable 13.87 12.22 28 25492 11625 34919786
Rectal cancer 13.71 12.22 12 25508 2195 34929216
Diabetes mellitus 13.63 12.22 69 25451 46804 34884607
Pancreatitis chronic 13.55 12.22 12 25508 2228 34929183
Hypoglycaemic unconsciousness 13.54 12.22 8 25512 790 34930621
Sleep talking 13.51 12.22 7 25513 535 34930876
Hepatic function abnormal 13.40 12.22 66 25454 44297 34887114
Neutropenia 13.30 12.22 64 25456 156714 34774697
Urogenital infection fungal 13.14 12.22 3 25517 16 34931395
Aortic stenosis 13.03 12.22 16 25504 4342 34927069
Metastases to liver 13.02 12.22 30 25490 13633 34917778
Diabetic retinal oedema 12.94 12.22 5 25515 190 34931221
Blood urine present 12.86 12.22 26 25494 10808 34920603
Blood urea increased 12.85 12.22 50 25470 30314 34901097
Rheumatoid arthritis 12.70 12.22 6 25514 38232 34893179
Cholelithiasis 12.59 12.22 39 25481 21109 34910302

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bladder cancer 2279.04 11.42 688 37816 18838 79687046
Hypoglycaemia 616.39 11.42 458 38046 101136 79604748
Blood glucose increased 481.07 11.42 417 38087 114558 79591326
Bladder transitional cell carcinoma 467.61 11.42 129 38375 2521 79703363
Cardiac failure congestive 260.41 11.42 332 38172 142070 79563814
Diabetes mellitus inadequate control 257.27 11.42 155 38349 24109 79681775
Diabetic ketoacidosis 213.67 11.42 157 38347 33965 79671919
Oedema peripheral 181.91 11.42 386 38118 251902 79453982
Glycosylated haemoglobin increased 173.67 11.42 111 38393 19149 79686735
Haematuria 144.23 11.42 172 38332 68664 79637220
Bladder neoplasm 135.08 11.42 45 38459 1692 79704192
Blood glucose decreased 134.10 11.42 107 38397 26127 79679757
Myocardial infarction 117.04 11.42 268 38236 183861 79522023
Pancreatitis 111.42 11.42 151 38353 68424 79637460
Pancreatic carcinoma 107.15 11.42 72 38432 13505 79692379
Diabetic metabolic decompensation 106.54 11.42 45 38459 3287 79702597
Drug ineffective 97.30 11.42 239 38265 1080674 78625210
Off label use 96.17 11.42 183 38321 907032 78798852
Cardiac failure 88.19 11.42 216 38288 154626 79551258
Hyperglycaemia 86.79 11.42 136 38368 70199 79635685
Macular oedema 85.23 11.42 45 38459 5429 79700455
Ureteric cancer 83.87 11.42 21 38483 276 79705608
Oedema 80.33 11.42 178 38326 119402 79586482
Transitional cell carcinoma 76.88 11.42 33 38471 2508 79703376
Weight increased 72.21 11.42 295 38209 277091 79428793
Coronary artery disease 69.13 11.42 118 38386 65356 79640528
Drug intolerance 67.01 11.42 22 38482 264097 79441787
Diabetic retinopathy 61.39 11.42 30 38474 3076 79702808
Acute myocardial infarction 57.84 11.42 120 38384 76916 79628968
Drug abuse 54.70 11.42 7 38497 162684 79543200
Hypoglycaemic coma 54.58 11.42 32 38472 4728 79701156
Pancreatitis acute 54.48 11.42 91 38413 49513 79656371
Infusion related reaction 52.03 11.42 23 38481 230214 79475670
Euglycaemic diabetic ketoacidosis 50.92 11.42 35 38469 6809 79699075
Lactic acidosis 49.80 11.42 107 38397 70252 79635632
Malignant spinal cord compression 48.70 11.42 12 38492 147 79705737
Rheumatoid arthritis 48.42 11.42 20 38484 208450 79497434
Diabetic nephropathy 48.08 11.42 25 38479 2922 79702962
Bladder cancer stage 0, with cancer in situ 47.22 11.42 10 38494 58 79705826
Treatment failure 45.39 11.42 13 38491 170473 79535411
Pemphigoid 43.68 11.42 45 38459 15270 79690614
Bladder cancer recurrent 42.47 11.42 14 38490 509 79705375
Bladder adenocarcinoma stage unspecified 40.64 11.42 8 38496 30 79705854
Genital infection fungal 40.50 11.42 11 38493 202 79705682
General physical health deterioration 40.36 11.42 44 38460 275194 79430690
Diabetes mellitus 39.03 11.42 104 38400 78286 79627598
Diabetic neuropathy 37.54 11.42 28 38476 6188 79699696
Maternal exposure during pregnancy 37.11 11.42 10 38494 136528 79569356
Contraindicated product administered 36.76 11.42 15 38489 157523 79548361
Cerebral infarction 36.47 11.42 73 38431 45603 79660281
Rhabdomyolysis 36.29 11.42 121 38383 103010 79602874
Lower respiratory tract infection 36.00 11.42 9 38495 129211 79576673
Angina unstable 35.75 11.42 42 38462 16485 79689399
Product use in unapproved indication 35.64 11.42 41 38463 250318 79455566
Product use issue 33.67 11.42 31 38473 209791 79496093
Glossodynia 33.42 11.42 5 38499 103332 79602552
Intentional product use issue 33.11 11.42 16 38488 152096 79553788
Cerebrovascular accident 32.62 11.42 155 38349 155137 79550747
Pulmonary oedema 32.35 11.42 105 38399 88149 79617735
Bladder papilloma 32.03 11.42 6 38498 16 79705868
Pleural effusion 31.99 11.42 147 38357 145115 79560769
Pericarditis 31.59 11.42 6 38498 104230 79601654
Urine cytology abnormal 30.83 11.42 5 38499 3 79705881
Dehydration 30.63 11.42 215 38289 247972 79457912
Retinal aneurysm 28.98 11.42 9 38495 269 79705615
Renal failure 28.97 11.42 181 38323 200787 79505097
Chest pain 28.89 11.42 234 38270 282070 79423814
Toxicity to various agents 28.51 11.42 106 38398 421434 79284450
Blood creatine phosphokinase increased 28.28 11.42 83 38421 66007 79639877
Alopecia 27.72 11.42 43 38461 231312 79474572
Retinal haemorrhage 26.85 11.42 26 38478 8191 79697693
Weight decreased 26.49 11.42 275 38229 354923 79350961
Meningitis eosinophilic 26.26 11.42 5 38499 15 79705869
Ketoacidosis 25.95 11.42 25 38479 7829 79698055
Product complaint 25.73 11.42 32 38472 13317 79692567
Bladder trabeculation 25.64 11.42 6 38498 58 79705826
Urethral cancer 24.78 11.42 6 38498 68 79705816
Exposure during pregnancy 24.63 11.42 9 38495 101123 79604761
Hypersensitivity 24.19 11.42 57 38447 262182 79443702
Arthropathy 24.13 11.42 30 38474 177081 79528803
Wound 24.11 11.42 13 38491 116166 79589718
Pancreatitis chronic 24.04 11.42 18 38486 4001 79701883
Prostate cancer 24.00 11.42 51 38453 33217 79672667
Blood triglycerides increased 23.63 11.42 39 38465 21001 79684883
Gallbladder neoplasm 23.55 11.42 6 38498 85 79705799
Blood glucose fluctuation 23.46 11.42 22 38482 6660 79699224
Visual acuity reduced 23.40 11.42 47 38457 29422 79676462
Fluid retention 22.88 11.42 80 38424 69729 79636155
Joint swelling 22.64 11.42 68 38436 288578 79417306
Therapeutic product effect incomplete 22.63 11.42 21 38483 141624 79564260
Acute kidney injury 22.56 11.42 364 38140 519040 79186844
Musculoskeletal stiffness 22.45 11.42 31 38473 174977 79530907
Hepatic function abnormal 22.44 11.42 82 38422 73025 79632859
Peripheral swelling 22.25 11.42 62 38442 269555 79436329
Pain 22.22 11.42 225 38279 703577 79002307
Discomfort 22.06 11.42 17 38487 125600 79580284
Hepatic cancer 21.52 11.42 26 38478 10503 79695381
Febrile neutropenia 21.47 11.42 50 38454 230949 79474935
Bladder transitional cell carcinoma stage III 21.13 11.42 5 38499 51 79705833
Coronary artery occlusion 20.83 11.42 31 38473 15284 79690600
Psoriatic arthropathy 20.65 11.42 6 38498 77993 79627891
Blood ketone body increased 20.61 11.42 9 38495 713 79705171
Cholelithiasis 20.52 11.42 64 38440 52600 79653284
Insulin resistance 20.52 11.42 11 38493 1368 79704516
Anti-insulin antibody positive 20.38 11.42 7 38497 289 79705595
Angina pectoris 20.28 11.42 63 38441 51669 79654215
Blood glucose abnormal 19.84 11.42 25 38479 10541 79695343
Fall 19.79 11.42 338 38166 487291 79218593
Nasopharyngitis 19.77 11.42 60 38444 253821 79452063
Lacunar infarction 19.75 11.42 19 38485 5938 79699946
Cardiomegaly 19.71 11.42 41 38463 26311 79679573
High density lipoprotein decreased 19.65 11.42 17 38487 4638 79701246
Ill-defined disorder 19.52 11.42 4 38500 65871 79640013
Pyrexia 19.40 11.42 222 38282 678487 79027397
IIIrd nerve paralysis 19.12 11.42 10 38494 1183 79704701
Bladder transitional cell carcinoma stage II 19.11 11.42 5 38499 79 79705805
Diabetic retinal oedema 19.06 11.42 7 38497 352 79705532
Biopsy skin abnormal 18.90 11.42 6 38498 193 79705691
Renal cyst 18.87 11.42 29 38475 14703 79691181
Stomatitis 18.82 11.42 26 38478 146731 79559153
Retinal exudates 18.79 11.42 10 38494 1225 79704659
Pancreatic carcinoma metastatic 18.52 11.42 15 38489 3738 79702146
Renal cell carcinoma 18.17 11.42 19 38485 6559 79699325
Hydronephrosis 17.81 11.42 31 38473 17423 79688461
Rash 17.78 11.42 186 38318 578172 79127712
Duodenal ulcer perforation 17.70 11.42 5 38499 66206 79639678
Arthralgia 17.54 11.42 184 38320 571619 79134265
Helicobacter infection 17.32 11.42 6 38498 69698 79636186
Folliculitis 17.19 11.42 3 38501 55377 79650507
Low density lipoprotein increased 17.15 11.42 21 38483 8601 79697283
Blood urea increased 16.94 11.42 57 38447 48733 79657151
Ketosis 16.80 11.42 9 38495 1117 79704767
Malignant neoplasm of renal pelvis 16.80 11.42 5 38499 129 79705755
Face oedema 16.79 11.42 40 38464 28096 79677788
Decreased appetite 16.77 11.42 245 38259 342173 79363711
Aortic stenosis 16.13 11.42 19 38485 7476 79698408
Fasting 15.81 11.42 4 38500 55 79705829
Fatigue 15.74 11.42 336 38168 929391 78776493
Diabetic complication 15.73 11.42 9 38495 1270 79704614
Microalbuminuria 15.59 11.42 8 38496 910 79704974
Blood creatinine increased 15.55 11.42 128 38376 154929 79550955
Chronic gastritis 15.46 11.42 14 38490 4054 79701830
Portal fibrosis 15.35 11.42 7 38497 614 79705270
Transient ischaemic attack 15.25 11.42 58 38446 52637 79653247
Multiple injuries 15.23 11.42 13 38491 3482 79702402
Isosporiasis 15.14 11.42 5 38499 183 79705701
Peripheral vascular disorder 15.08 11.42 19 38485 8011 79697873
Radius fracture 15.01 11.42 13 38491 3551 79702333
Hypoglycaemic encephalopathy 14.94 11.42 7 38497 654 79705230
Mucosal inflammation 14.90 11.42 9 38495 75571 79630313
Cardiac failure acute 14.80 11.42 30 38474 18899 79686985
Therapeutic product effect decreased 14.80 11.42 36 38468 163827 79542057
Blood pressure fluctuation 14.70 11.42 7 38497 67138 79638746
Fibula fracture 14.67 11.42 13 38491 3661 79702223
Cardiovascular disorder 14.61 11.42 29 38475 17996 79687888
Death 14.39 11.42 190 38314 566324 79139560
Infection 14.29 11.42 64 38440 241648 79464236
Adenocarcinoma pancreas 14.19 11.42 10 38494 2023 79703861
Asthenia 14.17 11.42 335 38169 511354 79194530
Infectious mononucleosis 14.15 11.42 10 38494 2032 79703852
Cardiac disorder 14.06 11.42 66 38438 65691 79640193
Abnormal weight gain 13.97 11.42 11 38493 2633 79703251
Sinusitis 13.96 11.42 48 38456 195453 79510431
Urogenital infection fungal 13.94 11.42 3 38501 19 79705865
Treatment noncompliance 13.88 11.42 56 38448 52212 79653672
Condition aggravated 13.87 11.42 165 38339 500959 79204925
Metastatic carcinoma of the bladder 13.78 11.42 5 38499 243 79705641
Hypoglycaemic unconsciousness 13.69 11.42 8 38496 1175 79704709
Pollakiuria 13.31 11.42 44 38460 37273 79668611
Therapy non-responder 13.25 11.42 15 38489 92290 79613594
Arteriosclerosis 13.21 11.42 28 38476 18199 79687685
Rectal cancer 13.18 11.42 12 38492 3501 79702383
Nausea 13.16 11.42 576 37928 956620 78749264
Renal impairment 13.11 11.42 125 38379 157658 79548226
Urine ketone body present 13.02 11.42 12 38492 3553 79702331
Polydipsia 13.00 11.42 16 38488 6589 79699295
Salpingo-oophorectomy bilateral 12.92 11.42 3 38501 28 79705856
Coma 12.73 11.42 18 38486 100631 79605253
Dilatation atrial 12.63 11.42 12 38492 3692 79702192
Interstitial lung disease 12.41 11.42 95 38409 112505 79593379
Ventricular hypertrophy 12.37 11.42 16 38488 6922 79698962
Varicose vein ruptured 12.36 11.42 4 38500 137 79705747
Nocturia 12.30 11.42 23 38481 13658 79692226
Hepatic enzyme increased 12.27 11.42 46 38458 182564 79523320
Tibia fracture 12.22 11.42 14 38490 5347 79700537
Loss of control of legs 12.20 11.42 9 38495 1956 79703928
Cellulitis 12.01 11.42 92 38412 108968 79596916
Neuropathic arthropathy 11.90 11.42 5 38499 360 79705524
Dry mouth 11.89 11.42 15 38489 88004 79617880
Adverse drug reaction 11.63 11.42 9 38495 66383 79639501
Sleep talking 11.61 11.42 7 38497 1089 79704795
Renal cancer 11.56 11.42 21 38483 12205 79693679
Humerus fracture 11.47 11.42 18 38486 9295 79696589
Urine flow decreased 11.46 11.42 7 38497 1114 79704770

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD09 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD12 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BG03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Thiazolidinediones
FDA CS M0199111 PPAR alpha
FDA CS M0199114 PPAR gamma
FDA CS M0447306 Thiazolidinediones
FDA MoA N0000175374 Peroxisome Proliferator-activated Receptor Activity
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
FDA MoA N0000175377 Peroxisome Proliferator-activated Receptor gamma Agonists
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:50864 insulin sensitizers
CHEBI has role CHEBI:71554 PPARgamma agonist
CHEBI has role CHEBI:77194 ATP:pantothenate 4-phosphotransferase inhibitor
CHEBI has role CHEBI:77307 cardioprotective agents
CHEBI has role CHEBI:83157 EC 6.2.1.3 inhibitors
CHEBI has role CHEBI:173084 ferroptosis inhibitors
CHEBI has role CHEBI:176497 geroprotectors
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist
FDA EPC N0000180186 Peroxisome Proliferator Receptor gamma Agonist
FDA EPC N0000180190 Thiazolidinedione

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Metabolic acidosis contraindication 59455009
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Autonomic dysreflexia contraindication 129618003
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.33 acidic
pKa2 7.15 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor AGONIST EC50 6.23 WOMBAT-PK CHEMBL
Bile salt export pump Transporter IC50 6.52 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 6.30 CHEMBL
Amine oxidase [flavin-containing] A Enzyme IC50 4.46 DRUG MATRIX
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor EC50 5.18 CHEMBL
CDGSH iron-sulfur domain-containing protein 1 Unclassified Ki 6.43 CHEMBL
Carbonic anhydrase 2 Enzyme IC50 6.94 DRUG MATRIX
CDGSH iron-sulfur domain-containing protein 2 Unclassified IC50 5.32 CHEMBL
Aldose reductase Enzyme IC50 4.88 DRUG MATRIX
Amine oxidase [flavin-containing] B Enzyme Ki 5.68 CHEMBL
Peroxisome proliferator-activated receptor alpha Transcription factor IC50 5.94 CHEMBL
Peroxisome proliferator-activated receptor gamma Transcription factor IC50 6.15 CHEMBL
Peroxisome proliferator-activated receptor gamma Transcription factor IC50 6.15 CHEMBL
Enoyl-[acyl-carrier-protein] reductase [NADH] Enzyme IC50 4.10 CHEMBL
Bile salt export pump Transporter IC50 5.70 CHEMBL
CDGSH iron-sulfur domain-containing protein 1 Unclassified IC50 6 CHEMBL

External reference:

IDSource
4021165 VUID
N0000148616 NUI
D00945 KEGG_DRUG
112529-15-4 SECONDARY_CAS_RN
4021165 VANDF
4021166 VANDF
4029214 VANDF
C0071097 UMLSCUI
CHEBI:8228 CHEBI
8N6 PDB_CHEM_ID
CHEMBL595 ChEMBL_ID
DB01132 DRUGBANK_ID
CHEMBL1715 ChEMBL_ID
D000077205 MESH_DESCRIPTOR_UI
4829 PUBCHEM_CID
2694 IUPHAR_LIGAND_ID
6343 INN_ID
X4OV71U42S UNII
259319 RXNORM
178611 MMSL
29092 MMSL
35713 MMSL
8258 MMSL
d04442 MMSL
007823 NDDF
007824 NDDF
116097005 SNOMEDCT_US
326058001 SNOMEDCT_US
395828009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0093-7271 TABLET 15 mg ORAL ANDA 29 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0093-7271 TABLET 15 mg ORAL ANDA 29 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0093-7272 TABLET 30 mg ORAL ANDA 29 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0093-7272 TABLET 30 mg ORAL ANDA 29 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0093-7273 TABLET 45 mg ORAL ANDA 29 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0093-7273 TABLET 45 mg ORAL ANDA 29 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5420 TABLET 15 mg ORAL ANDA 28 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5421 TABLET 30 mg ORAL ANDA 28 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5422 TABLET 45 mg ORAL ANDA 28 sections
Pioglitazone and metformin HUMAN PRESCRIPTION DRUG LABEL 2 0781-5626 TABLET, FILM COATED 15 mg ORAL ANDA 29 sections
Pioglitazone and metformin HUMAN PRESCRIPTION DRUG LABEL 2 0781-5627 TABLET, FILM COATED 15 mg ORAL ANDA 29 sections
Pioglitazone hydrochloride and glimepiride HUMAN PRESCRIPTION DRUG LABEL 2 0781-5634 TABLET 30 mg ORAL ANDA 28 sections
Pioglitazone hydrochloride and glimepiride HUMAN PRESCRIPTION DRUG LABEL 2 0781-5635 TABLET 30 mg ORAL ANDA 28 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0904-7090 TABLET 15 mg ORAL ANDA 30 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0904-7090 TABLET 15 mg ORAL ANDA 30 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0904-7096 TABLET 30 mg ORAL ANDA 30 sections
Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 1 0904-7096 TABLET 30 mg ORAL ANDA 30 sections
PIOGLITAZONEHYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-119 TABLET 30 mg ORAL ANDA 26 sections
PIOGLITAZONEHYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-120 TABLET 45 mg ORAL ANDA 26 sections
PIOGLITAZONEHYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 13668-140 TABLET 15 mg ORAL ANDA 26 sections
Pioglitazone HCL and Metformin HCL HUMAN PRESCRIPTION DRUG LABEL 2 13668-280 TABLET 15 mg ORAL ANDA 28 sections
Pioglitazone HCL and Metformin HCL HUMAN PRESCRIPTION DRUG LABEL 2 13668-281 TABLET 15 mg ORAL ANDA 28 sections
Pioglitazone Human Prescription Drug Label 1 16714-645 TABLET 15 mg ORAL ANDA 30 sections
Pioglitazone Human Prescription Drug Label 1 16714-646 TABLET 30 mg ORAL ANDA 30 sections
Pioglitazone Human Prescription Drug Label 1 16714-647 TABLET 45 mg ORAL ANDA 30 sections
PIOGLITAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16729-020 TABLET 15 mg ORAL ANDA 29 sections
PIOGLITAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16729-020 TABLET 15 mg ORAL ANDA 29 sections
PIOGLITAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16729-021 TABLET 30 mg ORAL ANDA 29 sections
PIOGLITAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16729-021 TABLET 30 mg ORAL ANDA 29 sections
PIOGLITAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16729-022 TABLET 45 mg ORAL ANDA 29 sections